As US Slows Down, Torrent Aims For Germany, Brazil
Indian Field Force Downsized
A lack of new launches and price erosion caused a sharp dip in Torrent’s Q3 US revenues, but the company plans to ramp up its presence in Brazil and Germany to build momentum. Meanwhile, the field force in India has been downsized with an aim to defocus on older brands.
You may also be interested in...
Two groups have issued largely complementary testing methods for measuring nitrosamine impurities in drugs, and the differences that do exist are “insignificant,” EDQM official advises. The two are working to further harmonize testing standards, given the global scope of the nitrosamine scare.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
With the India business on the road to recovery and the US growth outlook muted, Torrent hopes to keep the boat steady in fiscal 2021. It also expects an order in Q3 in a patent infringement case pertaining to AstraZeneca’s Farxiga, where it and multiple Indian firms are seeking to launch generic versions.